Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term randomized-withdrawal study of extended-release guanfacine in children and adolescents with ADHD
NL-OMON39353Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guanfacine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Takeda. Primary endpoint: Treatment failure during double-blind randomized-withdrawal phase. Started Oct 2011; status: active, not recruiting.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON39353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39353.